Interventions: Other: Placebo; Drug: Rezafungin
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting
Hide glossaryGlossary
Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Search for terms
x
Accepts healthy volunteers
Active comparator arm
Adverse event
Age or age group
All-cause mortality
Allocation
Arm
Arm type
Baseline characteristics
Canceled submission
Certain agreements
Certification
Certification/extension first posted
Certification/extension first submitted
Certification/extension first submitted that met QC criteria
City and distance
Clinical study
Clinical trial
ClinicalTrials.gov identifier (NCT number)
Collaborator
Condition/disease
Contact
Country
Cross-over assignment
Data Monitoring Committee (DMC)
Early Phase 1 (formerly listed as Phase 0)
Eligibility criteria
Enrollment
Exclusion criteria
Expanded access
Expanded access status
Expanded access type
Experimental arm
Extension request
Factorial assignment
First posted
First submitted
First submitted that met QC criteria
Food and Drug Administration Amendments Act of 2007, Section 801 (FDAAA 801)
Funder type
Gender-based eligibility
Group/cohort
Human subjects protection review board
Inclusion criteria
Informed consent
Informed consent form (ICF)
Intervention model
Intervention/treatment
Interventional study (clinical trial)
Investigator
Last update posted
Last update submitted
Last update submitted that met QC criteria
Last verified
Listed location countries
Location terms
Masking
NCT number
No intervention arm
Observational study
Observational study model
Other adverse event
Other study IDs
Other terms
Outcome measure
Parallel assignment
Participant flow
Patient registry
Phase
Phase 1
Phase 2
Phase 3
Phase 4
Phase Not Applicable
Placebo
Placebo comparator arm
Primary completion date
Primary outcome measure
Primary purpose
Principal investigator (PI)
Protocol
Quality control (QC) review
Randomized allocation
Recruitment status
Registration
Removed location countries
Reporting group
Responsible party
Results database
Results delayed
Results first posted
Results first submitted
Results first submitted that met QC criteria
Results returned after quality control review
Results submitted to ClinicalTrials.gov
Secondary outcome measure
Serious adverse event
Sex
Sham comparator arm
Single group assignment
Sort studies by
Sponsor
State
Statistical analysis plan (SAP)
Status
Study completion date
Study design
Study documents
Study IDs
Study record
Study registry
Study results
Study start date
Study type
Submitted date
Title
Title acronym
U.S. Agency for Healthcare Research and Quality (AHRQ)
U.S. Food and Drug Administration (FDA)
Unknown
Skip to Main Content
ClinicalTrials.gov
Find StudiesFind Studies Menu
About StudiesAbout Studies Menu
Submit StudiesSubmit Studies Menu
ResourcesResources Menu
About SiteAbout Site Menu
HomeSearch ResultsStudy Record Detail Save this study
Safety Study of Rezafungin to Treat Invasive Fungal Infections
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04117607
Recruitment Status : Not yet recruiting
First Posted : October 7, 2019
Last Update Posted : October 7, 2019
See Contacts and Locations
Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
Study DetailsTabular ViewNo Results PostedDisclaimerHow to Read a Study Record
Study Description
Go to sections
Brief Summary:
This is a Phase 1, double-blind, placebo-controlled trial in three parts. A single ascending dose (SAD) study in five cohorts receiving a single subcutaneous (SC) dose of 10, 30, 60, 100, or 200 mg of rezafungin; a multiple ascending dose (MAD) study in four cohorts receiving 30 mg x 3 doses, 60 mg x 3 doses, 100 mg x 3 doses, or 200 mg x 3 doses of rezafungin SC with dosing frequency of once every 7 days; and a two-period cross-over bioavailability (BA) study receiving 100 mg of rezafungin. The two period cross-over BA study will be assessed unblinded in two sequences (10 subjects, 100 mg or maximum tolerated dose (MTD) of rezafungin in Part 1); 5 subjects will receive an SC injection of rezafungin in Period 1 followed by an intravenous (IV) infusion of rezafungin in Period 2, and 5 subjects will receive an IV infusion of rezafungin in Period 1 followed by an SC injection of rezafungin in Period 2. Each SAD and MAD cohort will contain 8 subjects (6 subjects will receive a SC injection of rezafungin and 2 subjects will receive placebo). Each SAD and MAD cohort will be conducted with sentinel dosing. Part 2 of the study will only be conducted after FDA safety review of Part 1; Part 3 may be run in parallel with the final cohort of Part 1. Individuals in the SAD cohorts will participate for approximately 58 days, including up to 28 days for screening and 30 days for dosing and follow-up (FU). Individuals in the MAD cohorts will participate for approximately 73 days, including up to 28 days for screening and 45 days for dosing and FU. Individuals in the BA cohorts will participate for approximately 80 days, including up to 28 days for screening and 52 days for dosing and FU. The study will have a duration of approximately 15 months. The primary objectives are to determine the: 1) safety and tolerability of single ascending SC doses (SAD) of rezafungin; 2) safety and tolerability of multiple ascending SC doses (MAD) of rezafungin; and 3) pharmacokinetic (PK) profile in plasma of rezafungin in healthy adult subjects.
Condition or disease Intervention/treatment Phase
Fungal Infection
Other: Placebo
Drug: Rezafungin
Phase 1
Detailed Description:
This is a Phase 1, double-blind, placebo-controlled trial in three parts. A single ascending dose (SAD) study in five cohorts receiving a single subcutaneous (SC) dose of 10, 30, 60, 100, or 200 mg of rezafungin; a multiple ascending dose (MAD) study in four cohorts receiving 30 mg x 3 doses, 60 mg x 3 doses, 100 mg x 3 doses, or 200 mg x 3 doses of rezafungin SC with dosing frequency of once every 7 days; and a two-period cross-over bioavailability (BA) study receiving 100 mg of rezafungin. The two period cross-over BA study will be assessed unblinded in two sequences (10 subjects, 100 mg or maximum tolerated dose (MTD) of rezafungin in Part 1); 5 subjects will receive an SC injection of rezafungin in Period 1 followed by an intravenous (IV) infusion of rezafungin in Period 2, and 5 subjects will receive an IV infusion of rezafungin in Period 1 followed by an SC injection of rezafungin in Period 2. Each SAD and MAD cohort will contain 8 subjects (6 subjects will receive a SC injection of rezafungin and 2 subjects will receive placebo). Each SAD and MAD cohort will be conducted with sentinel dosing. Part 2 of the study will only be conducted after FDA safety review of Part 1; Part 3 may be run in parallel with the final cohort of Part 1. Individuals in the SAD cohorts will participate for approximately 58 days, including up to 28 days for screening and 30 days for dosing and follow-up (FU). Individuals in the MAD cohorts will participate for approximately 73 days, including up to 28 days for screening and 45 days for dosing and FU. Individuals in the BA cohorts will participate for approximately 80 days, including up to 28 days for screening and 52 days for dosing and FU. The study will have a duration of approximately 15 months. The primary objectives are to determine the: 1) safety and tolerability of single ascending SC doses (SAD) of rezafungin; 2) safety and tolerability of multiple ascending SC doses (MAD) of rezafungin; and 3) pharmacokinetic (PK) profile in plasma of rezafungin in healthy adult subjects. The secondary objective is to evaluate the bioavailability (BA) of rezafungin when administered by SC injection relative to IV infusion in healthy adult subjects.
Study Design
Go to sections
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 82 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase 1, Three-Part, Randomized, Double-Blind, Single and Multiple Subcutaneous Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of Rezafungin in Healthy Adult Subjects
Estimated Study Start Date : October 3, 2019
Estimated Primary Completion Date : January 1, 2021
Estimated Study Completion Date : January 1, 2021
Resource links provided by the National Library of Medicine
MedlinePlus related topics: Fungal Infections Molds
U.S. FDA Resources
Arms and Interventions
Go to sections
Arm Intervention/treatment
Experimental: BA1
100 mg (1 injection of 1.0 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered subcutaneously into the abdomen on Day 1, and 100 mg (250 ml) or MTD of Rezafungin administered via intravenous infusion on Day 22 in an open label manner. n=5.
Drug: Rezafungin
Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
Drug: Rezafungin
Rezafungin, 200 mg/vial, is a sterile product supplied as a white to pale yellow lyophilized powder in single-dose glass vials for reconstitution with Sterile Water for Injection, United States Pharmacopeia (USP). The reconstituted product is diluted in 0.9% Sodium Chloride Injection, USP for IV infusion. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredients include excipients of mannitol, polysorbate 80, and histidine.
Experimental: BA2
100 mg (250 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered via intravenous infusion on Day 1, and 100 mg (1 injection of 1.0 ml) or MTD of Rezafungin administered subcutaneously into the abdomen on Day 22 in an open label manner. n=5.
Drug: Rezafungin
Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
Drug: Rezafungin
Rezafungin, 200 mg/vial, is a sterile product supplied as a white to pale yellow lyophilized powder in single-dose glass vials for reconstitution with Sterile Water for Injection, United States Pharmacopeia (USP). The reconstituted product is diluted in 0.9% Sodium Chloride Injection, USP for IV infusion. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredients include excipients of mannitol, polysorbate 80, and histidine.
Experimental: MAD1
30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel) on Days 1, 8, and 15 in a double-blind manner.
Other: Placebo
0.9% Sodium Chloride Injection, USP, is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg and contains no preservatives, bacteriostatic agent, antimicrobial agent, or added buffer.
Drug: Rezafungin
Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
Experimental: MAD2
60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel) on Days 1, 8, and 15 in a double-blind manner.
Other: Placebo
0.9% Sodium Chloride Injection, USP, is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg and contains no preservatives, bacteriostatic agent, antimicrobial agent, or added buffer.
Drug: Rezafungin
Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
Experimental: MAD3
100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel) on Days 1, 8, and 15 in a double-blind manner.
Other: Placebo
0.9% Sodium Chloride Injection, USP, is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg and contains no preservatives, bacteriostatic agent, antimicrobial agent, or added buffer.
Drug: Rezafungin
Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
Experimental: MAD4
200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel) on Days 1, 8, and 15 in a double-blind manner.
Other: Placebo
0.9% Sodium Chloride Injection, USP, is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg and contains no preservatives, bacteriostatic agent, antimicrobial agent, or added buffer.
Drug: Rezafungin
Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
Experimental: SAD1
10 mg (1 injection of 0.1 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel) on Day 1 in a double-blind manner.
Other: Placebo
0.9% Sodium Chloride Injection, USP, is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg and contains no preservatives, bacteriostatic agent, antimicrobial agent, or added buffer.
Drug: Rezafungin
Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
Experimental: SAD2
30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel) on Day 1 in a double-blind manner.
Other: Placebo
0.9% Sodium Chloride Injection, USP, is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg and contains no preservatives, bacteriostatic agent, antimicrobial agent, or added buffer.
Drug: Rezafungin
Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
Experimental: SAD3
60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel) on Day 1 in a double-blind manner.
Other: Placebo
0.9% Sodium Chloride Injection, USP, is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg and contains no preservatives, bacteriostatic agent, antimicrobial agent, or added buffer.
Drug: Rezafungin
Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
Experimental: SAD4
100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel) on Day 1 in a double-blind manner.
Other: Placebo
0.9% Sodium Chloride Injection, USP, is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg and contains no preservatives, bacteriostatic agent, antimicrobial agent, or added buffer.
Drug: Rezafungin
Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
Experimental: SAD5
200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=-2 (1 sentinel, 1 non-sentinel) on Day 1 in a double-blind manner.
Other: Placebo
0.9% Sodium Chloride Injection, USP, is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg and contains no preservatives, bacteriostatic agent, antimicrobial agent, or added buffer.
Drug: Rezafungin
Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
Outcome Measures
Go to sections
Primary Outcome Measures :
Occurrence of abnormal ECG measurements for single ascending dose (SAD) [ Time Frame: Day 1 through Day 30 ]
ECG measurements include heart rate, RR interval, QT interval, QTcF interval, PR interval, and QRS duration.
Occurrence of abnormal laboratory test results for single ascending dose (SAD) [ Time Frame: Day 2 through Day 30 ]
Tests: complete blood count (CBC) with differential (red blood cell count, total and differential white blood cell counts, hemoglobin, hematocrit, platelet count), coagulation (activated partial thromboplastin time [APTT], prothrombin time [PT], international normalized ratio [INR]), clinical chemistry (albumin, glucose, blood urea nitrogen or urea, potassium, calcium, sodium, chloride, total protein, creatinine, triglycerides, total cholesterol, low-density lipoprotein cholesterol [LDL], high-density lipoprotein cholesterol [HDL], total carbon dioxide [CO2], creatine phosphokinase [CK], phosphorus, alkaline phosphatase, aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, direct bilirubin), dipstick urinalysis (protein, blood, glucose).
Occurrence of abnormal physical examination results for single ascending dose (SAD) [ Time Frame: Day 1 through Day 30 ]
Physical examination includes general appearance; head, eyes, nose and throat; neck; chest and lungs; cardiovascular system, abdomen, musculoskeletal system, lymph nodes, extremities/skin, and neurological system.
Occurrence of abnormal vital signs for single ascending dose (SAD) [ Time Frame: Day 1 through Day 30 ]
Vital sign measurements include body temperature, heart rate, respiration rate, and blood pressure.
Occurrence of Serious Adverse Events (SAEs) for single ascending dose (SAD) [ Time Frame: Day 1 through Day 30 ]
Occurrence of abnormal ECG measurements for multiple ascending doses (MAD) [ Time Frame: Day 1 through Day 15 ]
ECG measurements include heart rate, RR interval, QT interval, QTcF interval, PR interval, and QRS duration.
Occurrence of abnormal laboratory test results for multiple ascending dose (MAD) [ Time Frame: Day 2 through Day 45 ]
Tests: complete blood count (CBC) with differential (red blood cell count, total and differential white blood cell counts, hemoglobin, hematocrit, platelet count), coagulation (activated partial thromboplastin time [APTT], prothrombin time [PT], international normalized ratio [INR]), clinical chemistry (albumin, glucose, blood urea nitrogen or urea, potassium, calcium, sodium, chloride, total protein, creatinine, triglycerides, total cholesterol, low-density lipoprotein cholesterol [LDL], high-density lipoprotein cholesterol [HDL], total carbon dioxide [CO2], creatine phosphokinase [CK], phosphorus, alkaline phosphatase, aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, direct bilirubin), dipstick urinalysis (protein, blood, glucose).
Occurrence of abnormal physical examination results for multiple ascending dose (MAD) [ Time Frame: Day 1 through Day 45 ]
Physical examination includes general appearance; head, eyes, nose and throat; neck; chest and lungs; cardiovascular system, abdomen, musculoskeletal system, lymph nodes, extremities/skin, and neurological system.
Occurrence of abnormal vital signs for multiple ascending dose (MAD) [ Time Frame: Day 1 through Day 45 ]
Vital sign measurements include body temperature, heart rate, respiration rate, and blood pressure.
Occurrence of Serious Adverse Events (SAEs) for multiple ascending dose (MAD) [ Time Frame: Day 1 through Day 45 ]
Occurrence of Adverse Events (AEs) for single ascending dose (SAD) [ Time Frame: Day 1 through Day 30 ]
Occurrence of solicited local reactogenicity (injection site evaluation) for single ascending dose (SAD) [ Time Frame: Day 1 through Day 30 ]
Assessment of ecchymosis, erythema, induration, nodule, ulcer, healing, and scarring at injection site.
Occurrence of Adverse Events (AEs) for multiple ascending dose (MAD) [ Time Frame: Day 1 through Day 45 ]
Occurrence of solicited local reactogenicity (injection site evaluation) for multiple ascending dose (MAD) [ Time Frame: Day 1 through Day 45 ]
Assessment of ecchymosis, erythema, induration, nodule, ulcer, healing, and scarring at injection site.
Plasma levels of single ascending dose (SAD) [ Time Frame: Day 1 through Day 30 ]
Plasma levels of multiple ascending dose (MAD) [ Time Frame: Day 1 through Day 45 ]
Secondary Outcome Measures :
Bioavailability (BA) of Rezafungin, calculated as the ratio of the area under the curve (AUC) for the subcutaneous (SC) injection to the AUC for the intravenous (IV) infusion, where AUC is assessed by plasma Rezafungin levels [ Time Frame: Day 1 through Day 52 ]
Plasma rezafungin determined by LC-MS/MS methods.
Eligibility Criteria
Go to sections
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: 18 Years to 45 Years (Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes
Criteria
Inclusion Criteria:
Males and females aged 18 to 45 years, inclusive.
Willing and able to provide written informed consent and authorization for use of protected health information.
Willing and able to comply with protocol requirements, instructions, and protocol-stated restrictions (including confinement to the CRU) and is likely to complete the study as planned.
Males must be vasectomized or agree to use barrier contraception (condom with spermicide) from first dose of study drug until at least 18 weeks following the last dose of study drug.
Males must agree to refrain from sperm donation from first dose of investigational product (IP) through at least 18 weeks after last dose of IP.
Females are eligible to participate in this study if they are of non-childbearing potential*.
*Non-childbearing potential is defined as: Pre-menopausal with documentation of irreversible surgical sterilization (i.e., hysterectomy, bilateral oophorectomy, or bilateral salpingectomy (but not tubal ligation alone); or, Post-menopausal defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and with FSH levels > / = 40 mIU/mL at Screening.
Females of childbearing potential are eligible to participate if they are using a highly effective* method of contraception for 30 days prior to dosing and for a minimum of 30 days after dosing.
*A highly effective contraceptive method is, defined by < 1 percent failure rate that is not affected by user adherence, include surgical sterilization and long-acting reversible contraception (LARC). LARC comes in three forms: progestin-releasing subdermal implants (Nexplanon and Implanon [Merck]); copper intrauterine devices (IUD) (ParaGard [Teva]); and levonorgestrel-releasing IUDs (Mirena [Bayer], Skyla [Bayer], and Liletta [Allergan/Medicines360]. Subjects must use one of these three methods.
Subject is in good health as deemed by the Investigator*,**.
*Good health is defined by the absence of any medical condition described in the exclusion criteria in a subject who undergoes a medical history, with a normal complete physical examination including resting vital signs, and screening safety laboratory testing.
**If the subject has an active, ongoing medical condition, the condition cannot meet any of the following criteria: 1) first diagnosed within 3 months of enrollment; 2) is worsening in terms of clinical outcome in last 6 months; or 3) involves need for medication that may pose a risk to subject's safety or significantly impede assessment of adverse events if they participate in the study.
Subjects with a body mass index (BMI) (weight in kg divided by height in m, squared) between 18.5 and/or 35.0 kg/m^2, inclusive, and a minimum weight of 50 kg.
Subjects must refrain from strenuous physical activity that could cause muscle aches or injury, including contact sports, at any time from screening until completion of the trial.
Subjects must refrain from over-the-counter and prescription medications* and nutritional supplements within 14 days before first study drug administration, and until after the final study visit.
*except for hormonal contraceptives, acetaminophen, or ibuprofen.
Subject has adequate venous access for blood collection.
Exclusion Criteria:
History of any hypersensitivity or allergic reaction to echinocandins or excipients (mannitol, polysorbate 80, histidine) of the rezafungin for injection and rezafungin for infusion formulations.
Subjects presenting with a clinically significant condition*.
*Subjects with any of the following must not be included into the study: clinically significant oncologic, infectious, cardiovascular, pulmonary, hepatic, gastrointestinal, hematologic, metabolic, endocrine, neurologic, immunologic, renal, psychiatric, or other condition that in the opinion of the Investigator would preclude the safe participation of the subject in the study or would prevent the subject from meeting the study requirements.
Any condition that in the opinion of the Investigator could significantly impact drug absorption, distribution, or elimination.
Symptoms of acute illness or chronic disease within 14 days of initial dosing.
Positive screen for hepatitis B virus surface antigen, hepatitis C virus antibody, or HIV antibody.
Subjects with clinical laboratory values outside the site reference ranges* prior to initial dosing.
*Clinical laboratory values outside the site reference ranges, if considered by the site investigator to be clinically insignificant, are acceptable if not exceeding Grade 1 severity. One repeat of lab testing is allowed to make this determination during screening.
Abnormal ECGs.
Female subject of childbearing potential who is pregnant*, lactating, or planning to become pregnant during the study period or at least 30 days after the final dose of study product.
*Having a positive serum pregnancy test at the Screening Visit or any other specified time point prior to the dose of study product.
Received any prescription medications (except for hormonal contraceptives) within 14 days before first study drug administration.
Received any non-prescription medications, vitamins, herbal or dietary supplements* within 14 days of initial dosing, unless prior approval is granted by both the Investigator and the Sponsor.
*Excluded from this list is intermittent use of acetaminophen at doses of < / = 2 g/day or ibuprofen < / = 1200 mg/day. However, acetaminophen only is accepted to treat AEs for pain (ie. headaches) during in-clinic stay.
Current smoker or tobacco* use within 90 days prior to initial dosing or while a subject is enrolled in the study.
*Tobacco use includes vaping, smoking tobacco, the use of snuff and chewing tobacco, and other nicotine or nicotine-containing products
History of illicit/illegal drug use prior to dosing or while a subject is enrolled in the study* or reports an alcohol or substance abuse problem within 6 months of dosing.
*A urine drug test will be performed at screening and upon admission to the CRU. Drug screen includes amphetamines, barbiturates, cocaine, opiates, cannabinoids, phencyclidine, and benzodiazepines.
Consumed foods or beverages containing the following substances:
Alcohol: < / = 48 hours before the first study drug administration, until discharge.
Xanthines/caffeine: < / = 24 hours before the first study drug administration, until discharge.
Received any live or killed vaccines or immunoglobulins within 14 days of dosing.
Donated blood or blood products or experienced significant blood loss within 60 days of dosing.
Received a blood transfusion within 14 days of dosing.
Previous participation in this trial, any other rezafungin trial, or any trial* within 28 days of dosing. Plans to enroll in another clinical trial that could interfere with safety assessment of the investigational product at any time during the study period.
*Includes trials that have a study intervention such as a drug, biologic, or device.
The PI considers that the subject should not participate in the trial.
Contacts and Locations
Go to sections
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04117607
Contacts
Contact: Dennis Ruff 12102834572 dennis.ruff@iconplc.com
Locations
United States, Texas
ICON Early Phase Services Clinical Research Unit Not yet recruiting
San Antonio, Texas, United States, 78209-1015
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
More Information
Go to sections
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT04117607 History of Changes
Other Study ID Numbers: 17-0088
HHSN272201500007I
First Posted: October 7, 2019 Key Record Dates
Last Update Posted: October 7, 2019
Last Verified: September 2019
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Adults
CD101
Healthy
Intravenous
Rezafungin
Subcutaneous
Additional relevant MeSH terms:
Infection
Mycoses
TO TOP
For Patients and Families For Researchers For Study Record Managers
HOME RSS FEEDS SITE MAP TERMS AND CONDITIONS DISCLAIMER CUSTOMER SUPPORT
Copyright Privacy Accessibility Viewers and Players Freedom of Information Act USA.gov
U.S. National Library of Medicine U.S. National Institutes of Health U.S. Department of Health and Human Services
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου